Mednax Q4 EPS $0.47 ($0.52 adj); revenue $499M; FY22 EBITDA guidance at least $270M

Pediatrix Medical Group, Inc.

2021-FY EPS reported $1.53 revenue$1,911,191,000

GAAP EPS from continuing ops $0.47 versus $0.05 in Q4 2020; adjusted EPS $0.52 versus $0.25.
Revenue $498.5M (+20% YoY), driven by 17.6% same-unit growth (volume +6.3%, reimbursement +11.3%).
Adjusted EBITDA $81M in Q4 ($58.3M prior year); full-year 2021 $265.5M.
Preliminary 2022 adjusted EBITDA guidance at least $270M, excluding CARES Act funds.
Post-quarter refinancing: issued $400M 5.375% notes due 2030, new $450M revolver, $250M term loan; total debt $750M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.